acarbose	metformin	In overweight group, fasting blood glucose (FBG)	1035	1231	In overweight group, fasting blood glucose (FBG) after metformin treatment showed greater decline compared to acarbose group at 48 weeks [−1.73 (−1.99 to −1.46) vs. −1.37 (−1.61 to −1.12), P<0.05)
acarbose	metformin	After 48 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups 	17153	17358	. After 24 weeks and 48 weeks treatment, both acarbose and metformin treatment resulted in a significant decrease in waist circumference, hip circumference, weight and BMI in the three groups (all P<0.05).
acarbose	metformin	reduction of HbA1c levels	13106	13238	Both acarbose and metformin treatment significantly decreased HbA1c levels at 24 weeks and 48 weeks in the three groups (all P<0.05)
acarbose	metformin	In overweight group, fasting blood glucose (FBG)	1035	1234	In overweight group, fasting blood glucose (FBG) after metformin treatment showed greater decline compared to acarbose group at 48 weeks [−1.73 (−1.99 to −1.46) vs. −1.37 (−1.61 to −1.12), P<0.05), h
acarbose	metformin	After 24 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups 	17155	17357	After 24 weeks and 48 weeks treatment, both acarbose and metformin treatment resulted in a significant decrease in waist circumference, hip circumference, weight and BMI in the three groups (all P<0.05)
acarbose	metformin	After 48 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups 	17155	17357	After 24 weeks and 48 weeks treatment, both acarbose and metformin treatment resulted in a significant decrease in waist circumference, hip circumference, weight and BMI in the three groups (all P<0.05)
acarbose	metformin	reduction of HbA1c levels	874	1034	The reduction of HbA1c levels and the proportion of patients with HbA1c of 6.5% or less were similar in the three groups after acarbose and metformin treatment.
acarbose	metformin	After 24 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups 	17155	17487	After 24 weeks and 48 weeks treatment, both acarbose and metformin treatment resulted in a significant decrease in waist circumference, hip circumference, weight and BMI in the three groups (all P<0.05). The reduction of anthropometric measures was similar after acarbose or metformin treatment among normal weightand obesity groups
acarbose	metformin	After 48 weeks decrease in waist circumference, hip circumference, weight and BMI in the three groups 	17359	17449	The reduction of anthropometric measures was similar after acarbose or metformin treatment
